Global health authorities are pushing back against former U.S. President Donald Trump’s recent remarks suggesting a potential connection between Tylenol (acetaminophen) use during pregnancy and autism in children. Experts stress that the claim is not supported by credible scientific evidence.
Trump’s Claim Sparks Concern
During a public appearance, Trump referenced ongoing lawsuits in the United States that allege prenatal use of Tylenol may contribute to autism spectrum disorders. His comments quickly drew attention, raising concern among parents and health professionals.
Experts Say Evidence Is Inconclusive
Leading medical organizations, including the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC), responded by clarifying that current research does not prove a causal link between Tylenol and autism. While some observational studies have hinted at a possible association, experts note that such findings are limited and inconsistent.
“Correlation does not equal causation,” WHO officials emphasized, adding that more rigorous studies are needed before any conclusions can be drawn.
Doctors Urge Caution, Not Panic
Medical professionals advise pregnant women not to be alarmed by Trump’s remarks. Tylenol remains one of the most widely recommended pain relievers during pregnancy when used in proper doses.
Dr. Emily Johnston, a maternal-fetal medicine specialist, explained:
“Acetaminophen is generally safe when taken as directed. The potential risks suggested in small studies should not outweigh its benefits for women who need relief from fever or pain.”
Legal Battles Continue
In the U.S., lawsuits have been filed against drug manufacturers and retailers, claiming failure to warn about possible risks. However, no court has established Tylenol as a proven cause of autism, and regulatory agencies continue to list it as safe for use during pregnancy.
The Bottom Line
Health officials are urging the public to rely on medical guidance rather than political commentary. For now, Tylenol remains a recommended option for pregnant women, but experts encourage using the lowest effective dose for the shortest duration necessary.




















